ARCHIVES

Herceptin Regimen Minus Adriamycin Increases Survival With Less Toxicity

This article is from The Cancer Letter archive.

Vol. 34 No. 10 | October 28, 2011

Download PDF Visit The Full Archive

Related Articles

FDA Approves Erbitux for Head & Neck Cancer.

March 3, 2006

NCI Encourages IP Chemo For Stage III Ovarian Cancer

January 27, 2006

Studies of Oncotype DX Test Presented at ASCO Symposium

January 31, 2014

Von Eschenbach To Leave FDA Jan. 20, Says He Was “In Love” With The Agency.

December 19, 2008

Merger Of Centers, Control Programs An Option, Upton Says; ACS To Fund New Prevention Centers

February 2, 1979

NCI’s Future Depends On Recruiting Youth to Careers in Science, NCI Director Says at His Swearing-In Ceremony.

October 20, 2006